Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GALR3 | O60755 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | USP7 | Q93009 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15529688 | 0.82 | ALDH1A1 (0.52) | ALDH1A1GALR3MAPK1L3MBTL1LMNA | |
| SCHEMBL31289923 | 0.80 | MAPT (0.45) | TSHRALDH1A1GALR3MAPK1CTDSP1 | |
| SCHEMBL2448243 | 0.80 | KDM4E (0.42) | TSHRALDH1A1GALR3CTDSP1L3MBTL1 | |
| SCHEMBL3668043 | 0.80 | S1PR4 (0.43) | TSHRALDH1A1GALR3MAPK1CTDSP1 | |
| SCHEMBL2340132 | 0.80 | KDM4E (0.38) | TSHRALDH1A1GALR3MAPK1CTDSP1 | |
| SCHEMBL27961243 | 0.80 | S1PR4 (0.43) | TSHRALDH1A1GALR3MAPK1S1PR4 | |
| SCHEMBL23199502 | 0.77 | ERN1 (0.38) | TSHRALDH1A1GALR3CTDSP1L3MBTL1 | |
| SCHEMBL15685336 | 0.77 | KDM4E (0.36) | TSHRALDH1A1GALR3MAPK1CTDSP1 | |
| SCHEMBL14829147 | 0.76 | AHR (0.38) | TSHRALDH1A1GALR3CTDSP1L3MBTL1 | |
| SCHEMBL23199421 | 0.76 | CTDSP1 (0.36) | TSHRALDH1A1GALR3CTDSP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731966-B2 | Compounds and their methods of use | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2022255806-A1 | COMPOSITION FOR PREVENTING OR TREATING BRAIN CANCER | 연세대학교 산학협력단 | 2022-12-08 | — | — | WO | disclosed |
| US-7705042-B2 | Class of arylamide compounds useful as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-27 | — | — | US | disclosed |
| US-7705042-B2 | Class of arylamide compounds useful as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-27 | — | — | US | disclosed |
| US-7705042-B2 | Class of arylamide compounds useful as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-27 | — | — | US | disclosed |
| EP-1807407-B1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-29 | — | — | EP | disclosed |
| EP-1807407-B1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-29 | — | — | EP | disclosed |
| CN-101084208-A | Aromatic amides as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2007-12-05 | — | — | CN | disclosed |
| EP-1807407-A1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-18 | — | — | EP | disclosed |
| US-20060100201-A1 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-11 | — | — | US | disclosed |
| WO-2006047504-A1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731966-B2 | Compounds and their methods of use | SCN1A, SCN3A, SCN1B | TSHR 3804/4885ALDH1A1 916/4885GALR3 876/4885 |
| US-20060100201-A1 | Inhibitors of c-fms kinase | MUSK, FLT3, FES | TSHR 961/4885ALDH1A1 4796/4885GALR3 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.